old old OLD news. Exotic preclinical model.
eg old publication (and there are lots of them)- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3940660/
How about the 2b study which is clearly unpublishable. (I wonder what the FDA experts thought of the report). Any body can guess why?. Why has phase 2a (dose response should have been done 10 years ago.) not started yet? Phase 3 cannot start until robust clinical outcome of 2a particularly in more severe OA.
If this 2a.study does not show breakthrough pain and function improvements in severe OA this P3 trial is waste of time.
Ann: PAR REPORTS POSTIVE TOPLINE RESULTS IN HEART FAILURE MODEL, page-12
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.020(8.00%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 23.0¢ | $235.8K | 980.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 100000 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 6521 | 2 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |